Weekly Tech+Bio Highlights #78: AI Agents Rush In
Roche and Lilly scale up pharma's biggest AI supercomputers, a billion-dollar startup unveils its virtual cell, ex-GSK AI leaders launch startup, and agents are everywhere
Everyone seems to be building agents right now. In what looks akin to be the next “gold rush,” tech stacks are being rebuilt around them, open-source AI assistants are gaining traction fast, and major companies are pouring billions into autonomous systems while trimming headcount.
GTC 2026 brought that energy straight into life sciences. NVIDIA CEO Jensen Huang's keynote framed agentic AI as the next platform shift, and the life sciences sector seems to be taking that literally. Agents are now everywhere you look: IQVIA rolled out over 150 of them across clinical and commercial workflows, Insilico added one for translational biology, Latent Labs has one designing antibodies from text prompts, and NVIDIA itself unveiled a full surgical robotics stack.
We now have two top pharma companies in an apparent compute arms race within the same quarter. Roche's 3,500+ Blackwell GPUs positioned as the largest announced pharma GPU footprint, right on the heels of Lilly‘s LillyPod supercomputer and its $1B co-innovation lab with NVIDIA announced at JP Morgan. That's not incremental adoption, that's a structural commitment.
Startups are matching the energy: Xaira, backed by nearly $1 billion in funding, has now launched a 4.9-billion-parameter virtual cell model, Earendil, since our note of their plans for a ~$500M IPO last week, pulled in $787 million for AI-driven biologics, and the overall VC wave into AI-native bio keeps building. Speaking broadly of AI-native startups, Huang pointed to ~$150 billion in venture funding flowing their way last year.
Hi! This is BiopharmaTrend’s weekly newsletter, Where Tech Meets Bio, where we explore technologies, breakthroughs, and cutting-edge companies.
If this newsletter is in your inbox, it’s because you subscribed, or someone thought you might enjoy it. In either case, you can subscribe directly by clicking this button:
🤖 AI x Bio
(AI applications in drug discovery, biotech, and healthcare)
🔹 Roche launched its own large-scale AI computing hub for drug discovery, development, and manufacturing after buying 2,176 Blackwell GPUs (bringing its total capacity above 3,500), supporting model training, biological data analysis, lab-linked workflows, and factory digital twins.
🔹 AI reasons about protein function — Arc Institute researchers introduced a multimodal model for protein function prediction that combines protein embeddings with language-model reasoning, beating prior public benchmarks, generating step-by-step biological explanations, and earning preference over curated annotations in 79% of expert comparisons.
🔹 At GTC, UCL and partners unveiled what they describe as a first hybrid quantum-GPU biomolecular simulation pipeline, combining quantum hardware with 120 H100 GPUs to model a major drug-target protein class at realistic biological scale.
🔹 Xaira Therapeutics launched a 4.9-billion-parameter AI virtual cell model that predicts cellular responses to genetic perturbations, trained on 25.6 million perturbed single-cell transcriptomes and reported to generalize to unseen biological contexts.
🔹 Latent Labs, after coming out of stealth last February, launches an AI agent that designs therapeutic antibodies from text prompts in hours, reporting ~67% success with nanomolar affinities.
🔹 At GTC 2026, NVIDIA launched Proteina-Complexa, a generative protein binder design model accepted as an oral presentation at ICLR 2026, built on Proteina (ICLR 2025) and extending it to full atomistic binder design with inference-time compute scaling. Novo Nordisk, Manifold Bio, and Viva Biotech participated in wet lab validation. Other announcements also included a surgical robotics stack: Open-H (700+ hours of surgical video), Cosmos-H (synthetic surgical data generation), GR00T-H (vision-language-action model for clinical robotics), and Rheo (a simulation framework).
🔹 IQVIA launched a unified AI platform to support clinical, commercial, and real-world decision-making, with 150+ deployed agents, and 100+ AI patent filings.
🔹 Open-source protein design workflow — Dyno Therapeutics unveiled an open-source agentic AI suite for protein binder design that pairs generative models with lab-trained predictive filters.
🔹 Agentic AI for translational biology — Insilico Medicine launched a new AI analysis agent for therapeutic discovery that lets biologists use natural language to run multi-omics and bioinformatics workflows, drawing on 140+ scientific skills and 1,000+ tools.
🔹 To fix the experimental bottleneck, Arctoris opened a new biophysics center in the UK to generate drug-binding and protein-quality data at scale for AI-driven discovery.
🔹 Building a massive genomics dataset for AI — Basecamp Research launched a Trillion Gene Atlas to collect genomic data from 100+ million species, aiming to expand biological training data for AI models through global sampling.
🔹 AlphaFold adds protein interaction context — the AF database now includes 1.7 million predicted homodimer structures from an initial 30 million candidates, expanding beyond single proteins to capture how identical protein pairs may interact across 20 key organisms.
🔹 Automated labels can quietly worsen medical AI bias — Researchers found breast tumor segmentation models do far worse on younger patients for qualitative reasons, and training on machine-generated labels can amplify the disparity by ~40% while biased benchmarks can hide the damage.
💰 Money Flows
(Funding rounds, IPOs, and M&A for startups and smaller companies)
🔹 Earendil Labs raised $787 million to scale AI-driven antibody and biologics discovery, expand teams, and advance a pipeline of 40+ programs, including one program ready for Phase 2 and multiple regulatory filings planned for 2026-2027.
🔹 Neuracle‘s commercial approval triggered a funding wave across China’s BCI sector: Shanghai-based StairMed raised ~$73M for its robot-inserted flexible electrode approach, while Gestala pulled in $21M just two months after launch for a non-invasive ultrasound BCI platform.
🔹 Verily raised $300M and became an independent company, using the capital to expand its AI-ready health data platform, consumer health tools, and clinical/research agents while Alphabet shifts to a minority stake.
🔹 Rivia raised €13M to build AI agents for clinical trial operations, expanding its unified data platform to proactively flag risks, anomalies, and enrollment issues in regulated trial workflows.
⚙️ Other Tech
(Innovations across quantum computing, BCIs, gene editing, and more)
🔹 Nia Therapeutics received FDA Breakthrough Device status for an AI-guided brain implant aimed at memory loss after traumatic brain injury, with a study reporting a 19% recall improvement by detecting poor memory-encoding states and delivering targeted stimulation.
🔹 Brain activity restored after deep freezing — researchers in Germany revived key functions in vitrified mouse brain slices after storage at up to −150 °C for as long as seven days, preserving neuronal firing, metabolism, and synaptic plasticity.
🔹 ReVision Implant won FDA Breakthrough Device status for a brain-stimulation visual prosthesis designed to restore functional vision in blindness beyond the retina, with planned surgical testing in October 2026.
🔹 Mind typing nears everyday speeds — Massachusetts General Hospital researchers enabled two people with paralysis to type on a standard digital keyboard using brain implants that decode imagined finger movements, reaching 22 words per minute with low error after training on just 30 sentences.
🔹 “No, we haven’t uploaded a fly yet”—scientists push back on viral claims of a digital fruit fly, arguing the demo stitched together existing brain and body models with pre-programmed behaviors, falling far short of true whole-brain emulation.
🏛️ Bioeconomy & Society
(News on centers, regulatory updates, and broader biotech ecosystem developments)
🔹 FDA pushes shift beyond animal testing, issuing draft guidance to validate non-animal methods like organoids, lab models, and simulations for drug safety testing, aiming to replace animal studies with more predictive human-relevant data and speed clinical development.
🔹 NIH committed $150M investment in human-based research to reduce reliance on animal models, framed around its Complement-ARIE program.
🔹 arXiv’s move out of Cornell—Science reports it will become an independent nonprofit on July 1, 2026.
🚀 A New Kid on the Block
(Emerging startups with a focus on technology)
Former GSK AI Leaders Launch Stealth Oncology Startup — Shane Lewin and Nick Peterson, who both recently left GSK after six years building the pharma giant’s AI/ML and research data infrastructure, have co-founded Clockwork Bio (Lewin as CEO, Peterson as CTO).
The stealth-mode startup is building an AI-native platform for preclinical oncology drug discovery, arguing that conventional pipelines designed around heritable genetic targets fail for cancer, where disease is driven by epigenetic regulation, cell signaling, and lineage switching.
Their approach combines active learning, AI-based phenotyping, and emerging modalities to force cells between healthy and diseased states in vitro while learning the underlying biology at scale.
No funding or team details disclosed, formal product launch expected later in 2026.
Read also:
Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape